Cocrystal Pharma Discovers Pan-Viral Inhibitors for Hantavirus, Bunyavirus, and Influenza
COCP sits 43% above its 52-week low of $0.859.
Summary
Cocrystal Pharma announced the discovery of novel pan-viral inhibitors demonstrating *in vitro* potency against hantavirus, bunyavirus, and influenza. These compounds target a critical viral replication enzyme. This expands the company's pipeline beyond its norovirus candidate, CDI-988, which recently advanced to a Phase 1b study. However, the company's Q1 report confirmed a going concern warning and an urgent need for capital, with a $150 million shelf registration in place. The discovery addresses significant unmet medical needs, especially for hantavirus, which has a high fatality rate and no approved treatments. While very early stage, this scientific progress adds to the company's long-term potential. The company plans further *in vitro* evaluation and is seeking collaborations.
At the time of this announcement, COCP was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9M. The 52-week trading range was $0.86 to $2.67. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.